JW Jungwoo Pharmaceutical to Pursue Additional Technology Exports at JP Morgan Conference
[Asia Economy Reporter Cho Hyun-ui] JW Pharmaceutical is pursuing additional technology exports at the world's largest pharmaceutical and biotech investment event.
JW Pharmaceutical announced on the 2nd that it will hold one-on-one meetings with global investors at the JP Morgan Healthcare Conference, which will be held from the 13th (local time) in San Francisco, USA.
At this conference, JW Pharmaceutical plans to actively engage in open innovation for its major innovative new drug candidates developed in-house.
In particular, it will discuss additional technology partnership projects for the atopic dermatitis treatment ‘JW1601’ and the gout treatment ‘URC102’, which have been recognized for their value in the global market and successfully licensed out. First, it will reveal for the first time the strategy for expanding the indications and the development status of JW1601. JW1601 is a first-in-class innovative new drug candidate with a novel mechanism that selectively acts on the histamine H4 receptor to simultaneously suppress inflammation and itching. It is currently undergoing preclinical trials for ophthalmic diseases such as senile macular degeneration and allergic conjunctivitis, following atopic dermatitis.
Regarding URC102, JW Pharmaceutical plans to actively promote global technology transfer. Since it was licensed out to China in September last year, technology exports to other countries are also expected to gain momentum. Additionally, the latest research status and clinical development strategies for the Wnt-targeting anticancer drug ‘CWP291’, the Wnt-targeting hair loss treatment ‘CWL08061’, and the dendritic cell therapy ‘CreaVax (CreaVax)’ will also be explained.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Don't Throw Away Coffee Grounds" Transformed into 'High-Grade Fuel' in Just 90 Seconds [Reading Science]
- Signed Without Viewing for 1.6 Billion Won... Jamsil and Seongbuk Jeonse Prices Jump 200 Million Won in a Month [Real Estate AtoZ]
- [Breaking] President Lee: "Sharing operating profit before taxes are deducted?... I don't understand"
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
JW Pharmaceutical CEO Lee Sung-yeol said, “High interest is expected regarding JW’s research and development capabilities, which have been confirmed through consecutive technology exports.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
